• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Looking back at an EPAD-tastic 2016!

2017-01-27News

Another EPAD year has passed and we are proud to look back at a lot of successful deliveries and established relationships and look forward to 2017. To celebrate turning two, we list herein some of our key achievements of the past 12 months.

January

At the turn of the year, we welcomed the 36th EPAD partner to the project. Aridhia and its AnalytiXagility system will develop and manage the LCS data and analytics platform. http://ep-ad.org/2016/01/28/epad-selects-aridhia-data-platform/

May

May 10th, a date we will not easily forget, as the first EPAD Research Participant has joined the EPAD family by volunteering to participate in the EPAD Longitudinal Cohort Study (LCS). Achieving this milestone officially announced the start of one of the greatest endeavours in the Alzheimer’s Community – building one of the largest predementia research cohorts ever. http://ep-ad.org/2016/05/10/bid-to-prevent-alzheimers-dementia-signs-up-first-study-recruit/

Also in May, the second EPAD General Assembly took place in Barcelona. The meeting, hosted by EPAD partners the Barcelonaβeta Brain Research Center and sponsored by EPAD partner Eisai, was dedicated to discussing the initiation and delivery of the EPAD study platform as core objectives of the project. http://ep-ad.org/2016/05/17/epad-consortium-meeting-17-19-may-2016/

July

During the AAIC conference, EPAD organized, together with its American counterpart the Global Alzheimer’s platform, a joint session to discuss and present the global collaborative efforts in Alzheimer’s research. Similar initiatives are being developed as we speak in Australia, Canada & Japan. With this, EPAD wants to reinforce its commitment to global alignment and collaboration in Alzheimer’s prevention. http://ep-ad.org/2016/07/23/epad-features-prominently-at-aaic-conference-in-toronto/

October

EPAD publishes breakthrough recommendations for detection of early preclinical Alzheimer’s disease. In a time when prevention studies are becoming increasingly important, these recommendations were welcomed by the AD community. As EPAD will undertake large-scale proof-of-concept trials in predementia Alzheimer’s disease, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure. http://ep-ad.org/2016/10/11/epad-publishes-key-publications-for-detection-of-early-preclinical-alzheimers-dementia/

Also in October, we welcomed our sister IMI project – IMI Amypad. Amypad will investigate the value of β-amyloid using PET imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia. It may improve an early diagnosis of AD, and, when recognized in a pre-symptomatic population, even provide an opportunity for secondary prevention of AD. Especially for the latter, EPAD & Amypad will closely work together. http://ep-ad.org/2016/10/05/our-new-sister-project-amypad-officially-launches-today/

November

WP8 within EPAD recognizes the importance of considering the ethical, legal and social implications of research initiatives and the inclusion of research participant voices within the medical research process. A systematic review by EPAD has been published and examined the effects of disclosing genetic and nongenetic AD-related biomarkers to cognitively healthy research participants. http://ep-ad.org/2016/11/22/epad-paper-reviews-effects-of-disclosing-ad-biomarker-results-to-healthy-individuals/

Also in November, EPAD was delighted and honoured to have been involved in a conference organized by the Slovak Presidency of the European Union on “Alzheimer’s disease – epidemic of the third millennium: Are we ready to face it?” in Bratislava, which brought together over 100 experts from different EU Member States and provided an opportunity to highlight policy and research initiatives at global, European and national level. http://ep-ad.org/2016/11/29/epad-invited-to-speak-at-eu-presidency-conference/

About EPAD

EPAD aims to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD will establish a European-wide register of approximately 24,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the new @AlzheimerEurope report on #DataSharing in #dementia #research, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing. It includes case studies from ADNI, @IMI_EPAD and @IMI_EMIF. ⬇️ Bit.ly/DataSharing_AE twitter.com/AlzheimerEurop…

reply retweet favorite
2:39 pm · 2021-02-23
Twitter
EPAD
EPAD
@IMI_EPAD

Scottish @IMI_EPAD members have been invited to join the first #EPADcommunity meeting. Today, we're discussing about publications, #data access, communications, participant panel, #network & #collaborations. Nice to see some #epadistas sharing their insights 👨‍⚕️👩‍🔬👩‍💻 pic.twitter.com/O1hLAVxk0Q

reply retweet favorite
2:23 pm · 2021-02-17
Twitter
EPAD
EPAD
@IMI_EPAD

The new issue of the @IMI2_NEURONET #newsletter is out with latest news on @IMI_EPAD, @IMI_AMYPAD, @RADARCNS among others. Find out more here: bit.ly/Neuronet-Newsl… twitter.com/IMI2_NEURONET/…

reply retweet favorite
2:12 pm · 2021-02-15
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.